News & Updates

Show Multimedia Only
Survival advantage in COVID-19 seen with 8-mg/kg tocilizumab

Survival advantage in COVID-19 seen with 8-mg/kg tocilizumab

09 Feb 2023

In the treatment of hospitalized patients with COVID-19, survival outcomes appear to be more favourable with the 8-mg/kg tocilizumab regimen than with the fixed-dose tocilizumab regimen or sarilumab, according to a study.

09 Feb 2023
Studies support vedolizumab benefit for IBD

Studies support vedolizumab benefit for IBD

07 Feb 2023 byAudrey Abella

Data presented at the Crohn’s & Colitis Congress (CCC) 2023 reflect the benefit of vedolizumab for inflammatory bowel disease (IBD; Crohn’s disease and ulcerative colitis), be it alone or in a combination regimen. In one study however, extraintestinal manifestations were observed following vedolizumab use.

07 Feb 2023